Patent US5233997A successfully refreshed from Google Patents.
US5233997A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Non-invasive measure of intestinal transit time and uses thereof
Assignee: Baylor College of Medicine
•
Filing: 1991-04-04
•
Granted: 1993-08-10
•
Expires: 2011-04-04
Abstract
Abstract A measurement test for gastrointestinal transit time, including the steps of administering a dose of labeled glycosyl ureide, measuring the labeled CO 2 and determining the amount of CO 2 over time is described. The assay can be used for measuring the effectiveness of drugs, the effect of drugs on gastrointestinal motility diagnoses of gastrointestinal motility disease measuring the effectiveness of treatment, and the effect of diet on motility.
Inventors
- 👤 Peter D. Klein
- 👤 Willi E. K. Heine
- 👤 Heiner K. Berthold
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-08 03:59
CPC Classifications
A; A61; A61K; A61K51/00; A61K51/02; A61K51/04; A61K51/0491; A61K2123/00
Claims Analysis
Total Claims: 13
Claim 1
Independent Claim
45 words
A non-invasive method for determining intestinal transit time, comprising the steps of: administering an oral testing dose of labeled glycosyl ureide to a subject to be tested; sampling respiratory gas over time from said subject; and measuring the amount of label in said respiratory gas.
Claim 2
Dependent Claim
45 words
A non-invasive method for determining intestinal transit time, comprising the steps of: administering an oral testing dose of labeled glycosyl ureide to a subject to be tested; sampling respiratory gas over time from said subject; and measuring the amount of label in said respiratory gas.
Claim 3
Dependent Claim
38 words
The method of claim 1 wherein the labeled glycosyl ureide is selected from the group consisting of lactose- 13 C-ureide, cellobiose- 13 C-ureide and 1- 13 C-lactose ureide; and 13 CO 2 is measured in said respiratory gas.
Claim 4
Dependent Claim
32 words
A method of diagnosing intestinal motility disease, comprising the steps of: performing the non-invasive test of claim 1 to determine the transit time; and comparing said transit time with normal transit time.
Claim 5
Dependent Claim
37 words
A method of monitoring the effectiveness of treatment of intestinal motility disease, comprising the steps of: measuring the transit time by the method of claim 1; administering the treatment; and repeating said measuring the transit time step.
Claim 6
Dependent Claim
47 words
A method for measuring the effect of drugs or diet on gastrointestinal tract motility, comprising the steps of: measuring the transit time by the method of claim 1; altering the diet or orally administering the drug to be tested; and repeating said measuring the transit time step.
Claim 7
Dependent Claim
17 words
The method of claim 1, wherein the dose of labeled glycosyl ureide is 10 to 20 mg/kg.
Claim 8
Dependent Claim
20 words
The method of claim 1, wherein the oral dose of label is equivalent to 1 to 5 mg/kg of urea.
Claim 9
Dependent Claim
15 words
The method of claim 7, wherein the label is equivalent to 2.5 mg/kg of urea.
Claim 10
Dependent Claim
18 words
The method of claim 1, wherein the respiratory gas is sampled at half-hour intervals, up to 24 hours.
Claim 11
Dependent Claim
69 words
A non-invasive method for determining intestinal transit time, comprising the steps of: administering an oral dose of labeled glycosyl ureide of 10 to 20 mg/kg of body weight to a subject to be tested; sampling respiratory gas by collecting said gas at 30 minutes, 60 minutes and every hour thereafter up to 24 hours after administering the labeled glycosyl ureide; and measuring the amount of label in said samples.
Claim 12
Dependent Claim
69 words
A non-invasive method for determining intestinal transit time, comprising the steps of: administering an oral dose of labeled glycosyl ureide of 10 to 20 mg/kg of body weight to a subject to be tested; sampling respiratory gas by collecting said gas at 30 minutes, 60 minutes and every hour thereafter up to 24 hours after administering the labeled glycosyl ureide; and measuring the amount of label in said samples.
Claim 13
Dependent Claim
37 words
The method of claim 10 wherein the glycosyl ureide is selected from the group consisting of lactose- 13 C-ureide, cellobiose- 13 C-ureide and 1- 13 C-lactose ureide; and 13 CO 2 is measured in said respiratory gas.
References Cited (Backward Citations)
US3852413A
Cited
CA1037768A
Cited
US4203967A
Cited
US4171352A
Cited
US4382887A
Cited
US4351823A
Cited
JPS58161987A
Cited
US4670245A
Cited
US4676974A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1996-08-09 | 1997-02-08 | 1997-08-10 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2000-08-09 | 2001-02-08 | 2001-08-10 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2004-08-09 | 2005-02-08 | 2005-08-10 | $7700.00 | Window Closed / Lapsed |